MedShape, Inc. A.I CyberSecurity Scoring
22/02/2026
Access Monitoring Plan
Access Monitoring Plan
No incidents recorded for MedShape, Inc. in 2026.
No incidents recorded for MedShape, Inc. in 2026.
No incidents recorded for MedShape, Inc. in 2026.
BD is one of the largest global medical technology companies in the world and is advancing the world of health™ by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com. See community guidelines here: https://tinyurl.com/yunjmzkx.
Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We advance our mission to alleviate pain and improve the quality of life for patients around the world with our innovative products and suite of integrated digital and robotic technologies leverage data, data analytics and artificial intelligence. Founded in 1927 and based in Warsaw, Zimmer Biomet has operations in more than 25 countries and sales in more than 100 countries. We maintain world-class scientific facilities and resources and collaborate with leading clinicians and researchers around the world. Awards and Recognitions • Forbes: America's Best Companies 2026 • Workhuman: Luminary Award 2025 & Innovator Award 2024 • TIME: America's Best Companies [Mid-Size] 2024 • Great Place to Work - Best Workplaces: Switzerland & Poland 2025 • Great Place to Work Certified 2025 - 2026: USA, Poland, India, Colombia, Ireland, Puerto Rico, Kingdom of Saudi Arabia, Switzerland • MedTech: Breakthrough Award Best New Technology Solution in Orthopedics 2025 • Top Employers Institute: China 2025 • VETS Indexes: 4 Star Employer 2025
Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside its customers around the world, Stryker impacts more than 150 million patients annually. More information is available at stryker.com and careers.stryker.com. Facts: ● 2024 Sales: $22.6 billion ● Industry: Medical Instruments & Supplies ● Employees: 53,000 worldwide ● 44+ Manufacturing and R&D Locations Worldwide ● $1.5 billion spent on research and development in 2024 ● ~14,200 patents owned globally in 2024 ● Products sold in ~75 countries ● Fortune 500 Company ● 9 consecutive years as one a World's Best Workplace Stryker’s social media community guidelines: https://www.stryker.com/content/m/legal/social-media-community-guidelines/en/index.html Notice Regarding Employee Conduct on Facebook/LinkedIn Meta/LinkedIn does not permit employers to verify or validate “employees” in the (META: “Works at” LinkedIn: “Experience”) section of users’ profiles. Please be aware that the views expressed by individuals on their personal accounts and do not necessarily represent the views of our company. If you encounter any issues with a person claiming to be our employee, we recommend using the “Report Profile” feature. If you’d like to report concerns to our Ethics Hotline, you may do so at: https://app.convercent.com/en-us/LandingPage/b6bb4e84-9fcb-ea11-a974-000d3ab9f296
Olympus is passionate about creating customer-driven solutions for the medical industry. For more than 100 years, Olympus has focused on making people’s lives healthier, safer and more fulfilling by helping detect, prevent, and treat disease, furthering scientific research, and ensuring public safety. Olympus is headquartered in Tokyo, Japan, with more than 31,000 employees worldwide in nearly 40 countries and regions.
Boston Scientific transforms lives through innovative medical technologies that improve the health of patients around the world. As a global medical technology leader for more than 40 years, we advance science for life by providing a broad range of high-performance solutions that address unmet patient needs and reduce the cost of health care. Our portfolio of devices and therapies helps physicians diagnose and treat complex cardiovascular, respiratory, digestive, oncological, neurological and urological diseases and conditions. For more information, visit www.bostonscientific.com and connect with us on X, Instagram, and Facebook. At Boston Scientific, you will find purpose, a place to grow and opportunities to cultivate your passions. To search and apply for open positions, visit https://bostonscientific.eightfold.ai/careers. You may also review our social media guidelines at http://www.bostonscientific.com/social.
STERIS is a leading provider of infection prevention and other procedural products and services, focused primarily on healthcare, pharmaceutical and medical device Customers. MISSION WE HELP OUR CUSTOMERS CREATE A HEALTHIER AND SAFER WORLD by providing innovative healthcare and life science products and services around the globe. VISION We strive to be a GREAT COMPANY. We provide world-class products and services for our Customers, safe and rewarding work for our people, and superior returns for our Shareholders. • $5 Billion in revenue in FY24 • More than 17,000 Associates worldwide • Over 4,000 Customer-facing professionals • Listed on the New York Stock Exchange under the symbol “STE” To learn more, visit www.steris.com. Want to join the team? View and apply for open roles at careers.steris.com.
Edwards Lifesciences (NYSE: EW), is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence and partnerships with clinicians and healthcare stakeholders, our employees are inspired by our patient-focused culture to deliver life-changing innovations to those who need them most. We thrive on discovery and expanding the boundaries of medical technology, serving patients in 100+ countries, with the help of our employees in areas including Clinical Affairs, Quality Engineering, Research & Development, Regulatory Affairs, Sales & Marketing, corporate functions and more. Contact Us We want to hear from you and engage in meaningful discussions. However, please note that we are not equipped to provide customer, candidate, or technical support through this platform. If you require assistance from those teams, please find their contact information here: https://www.edwards.com/aboutus/contactus If you’re a patient in need of medical advice, please contact your healthcare provider directly. We reserve the right to remove any comments that are off-topic, repetitive, or include hate speech, profanity, or offensive language. Additionally, we will not engage in discussions about competitor products, off-label use of Edwards products, or unsubstantiated/misleading claims that could cause harm. All Terms and Conditions of LinkedIn apply. For the Edwards Lifesciences privacy policy, visit https://www.edwards.com/legal/privacypolicy.
We are dedicated to transforming lives by improving the journey to a healthy, beautiful smile. Discover your straight path to a bright future at Align Technology. As a part of our smart, diverse and fast-moving global team, you'll make an impact on the market leader that's moving an industry forward. Want to find out what's next for us—and for you? Follow us on LinkedIn for business updates and check out our current opportunities at www.aligntech.com/careers. 25 years ago, we pioneered the market for clear aligners. Since then, we have continuously innovated with new products and technologies that revolutionize treatments for doctors and their patients. Today, doctors and labs in over 100 markets use the Invisalign system, iTero intraoral scanners and exocad software to improve smiles for patients – from simple tooth alignment to complex corrections, kids to adults, orthodontics to multi-disciplinary restorative treatment. Learn more about Align Technology and our products: www.aligntech.com www.invisalign.com www.itero.com www.exocad.com
A global leader in advanced diagnostics, Beckman Coulter has challenged convention to elevate the diagnostic laboratory’s role in improving patient health for more than 80 years. Our mission is to Relentlessly Reimagine Healthcare, One Diagnosis at a Time – and we do this by applying the power of science, technology and the passion and creativity of our teams. Our diagnostic solutions are used in complex clinical testing, and are found in hospitals, reference laboratories and physician office settings around the globe. We exist to deliver smarter, faster diagnostic solutions that move the needle forward from what’s now to what’s next. We do this by accelerating care with an extensive clinical menu, scalable lab automation technologies, insightful clinical informatics, and optimize lab performance services. Headquartered in Brea, Calif., Beckman Coulter Diagnostics has more than 11,000 global team members. Beckman Coulter is proud to be part of Danaher. Danaher is a global science and technology leader. Together we combine our capabilities to accelerate the real-life impact of tomorrow’s science and technology to improve human health.
Latest updates, reports, and threat intel affecting the global network.
OpenSIPS is a Session Initiation Protocol (SIP) server implementation. In versions prior to 3.6.6 and 4.0.0-rc1, the construct_uri() function concatenates multiple URI components (protocol, username, domain, port, params) into a fixed 1024-byte global BSS buffer without any bounds checking. When a routing script calls construct_uri() with an attacker-controlled username, a combined component length exceeding 1024 bytes overflows the buffer, corrupting adjacent global data with attacker-controlled content. The overflow reaches disable_503_translation, a global flag controlling SIP 503 response handling, allowing an attacker to deterministically set the flag via the URI username and alter the server's routing behavior for subsequent messages. Because the same buffer is shared with contact_builder(), the overflow also corrupts that function's data, and without a memory sanitizer the adjacent globals are silently overwritten on every request containing a long username. This issue has been fixed in versions 3.6.6 and 4.0.0-rc1.
A security vulnerability has been detected in RackTables up to 0.22.0/e5fff9f8aab339798ed47e8c6d7d977ed97a82bd. This vulnerability affects unknown code. The manipulation leads to cross-site request forgery. The attack is possible to be carried out remotely. The exploit has been disclosed publicly and may be used. The project maintainer confirms: "[I]t seems plausible, in that RackTables does not at this time have any CSRF prevention. You may assign a CVE ID to this, but there is no guarantee it will be handled in urgent, or even timely, manner, or at all."
A weakness has been identified in Ehco1996 django-sspanel up to 2023.12.26. This affects the function TicketDetailView of the file apps/sspanel/views.py of the component Support Ticket Handler. Executing a manipulation can lead to authorization bypass. The attack can be executed remotely. The vendor was contacted early about this disclosure but did not respond in any way. This vulnerability only affects products that are no longer supported by the maintainer.
Odysseus before commit 87babb5 contains a server-side request forgery vulnerability that allows admin-privileged attackers to direct the server to probe internal network resources by supplying arbitrary URLs to the embedding endpoint configuration without scheme, host, IP range, or DNS rebind validation. Attackers can submit loopback addresses, RFC 1918 ranges, or link-local addresses through the embedding endpoint API to partially read responses from cloud instance metadata services, internal APIs, and other hosts reachable from the server.
Odysseus before commit bf325f6 contains a missing authorization vulnerability that allows authenticated non-admin users to manage server-wide embedding backend configuration by invoking endpoint management routes that verify session authentication but omit the admin authorization guard. Attackers can supply an attacker-controlled URL to overwrite the embedding backend persisted in the endpoint configuration file and process environment, causing all subsequent embedding operations including chat messages, RAG queries, memory entries, and vault text to be transmitted in plaintext to the attacker-controlled destination, or delete the endpoint configuration to deny embedding service to all users.
curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'
Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.
Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.